Giorgia Giussani

List of Publications by Year
in descending order

74 papers	66,329 citations	81743 39 h-index	79541 73 g-index
77 all docs	77 docs citations	77 times ranked	92476 citing authors

#	Article	IF	Citations
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1789-1858.	6.3	8,569
2	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1211-1259.	6.3	5,578
3	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1545-1602.	6.3	5,298
4	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1736-1788.	6.3	4,989
5	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	6.3	4,951
6	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
7	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	6.3	4,203
8	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	6.3	3,565
9	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1923-1994.	6.3	3,269
10	Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 459-480.	4.9	2,625
11	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	6.3	2,184
12	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1859-1922.	6.3	2,123
13	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1345-1422.	6.3	1,879
14	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	6.3	1,612
15	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	6.3	1,589
16	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	6.3	1,544
17	Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurology, The, 2017, 16, 877-897.	4.9	1,521
18	Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1684-1735.	6.3	716

#	ARTICLE	IF	CITATIONS
19	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. Lancet, The, 2018, 391, 2236-2271.	6.3	638
20	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	6.3	573
21	Global, regional, and national burden of epilepsy, 1990â€"2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurology, The, 2019, 18, 357-375.	4.9	526
22	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€"2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	6.3	480
23	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	6.3	413
24	Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 2091-2138.	6.3	335
25	Population and fertility by age and sex for 195 countries and territories, 1950â€"2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2018, 392, 1995-2051.	6.3	294
26	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1423-1459.	6.3	284
27	Burden of Neurological Disorders Across the US From 1990-2017. JAMA Neurology, 2021, 78, 165.	4.5	262
28	The natural history and prognosis of epilepsy. Epileptic Disorders, 2015, 17, 243-253.	0.7	152
29	Withdrawal of antiepileptic drugs: Guidelines of the <scp>I</scp>talian <scp>L</scp>eague <scp>A</scp>gainst <scp>E</scp>pilepsy. Epilepsia, 2013, 54, 2-12.	2.6	112
30	Aging and the Epidemiology of Epilepsy. Neuroepidemiology, 2018, 51, 216-223.	1.1	101
31	Physical activity and amyotrophic lateral sclerosis: A European populationâ€"based caseâ€"control study. Annals of Neurology, 2014, 75, 708-716.	2.8	79
32	Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 397-405.	1.1	68
33	Trauma and amyotrophic lateral sclerosis: a caseâ€"control study from a populationâ€"based registry. European Journal of Neurology, 2012, 19, 1509-1517.	1.7	63
34	The semiology of psychogenic nonepileptic seizures revisited: Can video alone predict the diagnosis? Preliminary data from a prospective feasibility study. Epilepsia, 2016, 57, 777-785.	2.6	57
35	Adult-Onset Epilepsy in Presymptomatic Alzheimerâ€™s Disease: A Retrospective Study. Journal of Alzheimer's Disease, 2017, 60, 1267-1274.	1.2	57
36	Italy's health performance, 1990â€"2017: findings from the Global Burden of Disease Study 2017. Lancet Public Health, The, 2019, 4, e645-e657.	4.7	54

#	ARTICLE	IF	CITATIONS
37	Incidence of neonatal seizures, perinatal risk factors for epilepsy and mortality after neonatal seizures in the province of Parma, Italy. Epilepsia, 2018, 59, 1764-1773.	2.6	51
38	Coffee and Amyotrophic Lateral Sclerosis: A Possible Preventive Role. American Journal of Epidemiology, 2011, 174, 1002-1008.	1.6	50
39	Validation of healthcare administrative data for the diagnosis of epilepsy. Journal of Epidemiology and Community Health, 2013, 67, 1019-1024.	2.0	41
40	Acute and post-acute neurological manifestations of COVID-19: present findings, critical appraisal, and future directions. Journal of Neurology, 2022, 269, 2265-2274.	1.8	39
41	Prevalence and Incidence of Epilepsy in Italy Based on a Nationwide Database. Neuroepidemiology, 2014, 43, 228-232.	1.1	34
42	Long‐term applicability of the new <scp>ILAE</scp> definition of epilepsy. Results from the <scp>PRO</scp>‐<scp>LONG</scp> study. Epilepsia, 2017, 58, 1518-1523.	2.6	31
43	Prevalence and incidence of epilepsy in a well‐defined population of Northern Italy. Epilepsia, 2014, 55, 1526-1533.	2.6	28
44	A population-based study of active and drug-resistant epilepsies in Northern Italy. Epilepsy and Behavior, 2016, 55, 30-37.	0.9	28
45	Trauma and amyotrophic lateral sclerosis: a european population-based case-control study from the EURALS consortium. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 118-125.	1.1	26
46	Prognostic patterns and predictors in epilepsy: a multicentre study (PRO-LONG). Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 1276-1285.	0.9	26
47	Long‐term prognosis of epilepsy, prognostic patterns and drug resistance: a population‐based study. European Journal of Neurology, 2016, 23, 1218-1227.	1.7	24
48	Comorbidities in patients with epilepsy: Frequency, mechanisms and effects on long‐term outcome. Epilepsia, 2021, 62, 2395-2404.	2.6	22
49	Incidence, prevalence and disability associated with neurological disorders in Italy between 1990 and 2019: an analysis based on the Global Burden of Disease Study 2019. Journal of Neurology, 2022, 269, 2080-2098.	1.8	21
50	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane Library, 2016, , CD007144.	1.5	20
51	Antiepileptic drug discontinuation by people with epilepsy in the general population. Epilepsia, 2017, 58, 1524-1532.	2.6	19
52	Patients' and caregivers' contributions for differentiating epileptic from psychogenic nonepileptic seizures. Value and limitations of self-reporting questionnaires: A pilot study. Seizure: the Journal of the British Epilepsy Association, 2017, 53, 66-71.	0.9	15
53	Neonatal, infant, and under-5 mortality and morbidity burden in the Eastern Mediterranean region: findings from the Global Burden of Disease 2015 study. International Journal of Public Health, 2018, 63, 63-77.	1.0	15
54	Engaging psychiatrists in the diagnosis of psychogenic nonepileptic seizures. What can they contribute?. Seizure: the Journal of the British Epilepsy Association, 2017, 52, 182-187.	0.9	14

#	Article	IF	Citations
55	Satisfaction with antiepileptic drugs in children and adolescents with newly diagnosed and chronic epilepsy. Epilepsy Research, 2012, 100, 142-151.	0.8	13
56	Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?. CNS and Neurological Disorders - Drug Targets, 2013, 12, 426-435.	0.8	13
57	Rapid versus slow withdrawal of antiepileptic monotherapy in 2-year seizure-free adult patients with epilepsy (RASLOW) study: a pragmatic multicentre, prospective, randomized, controlled study. Neurological Sciences, 2016, 37, 579-583.	0.9	12
58	Survey on the worldwide availability and affordability of antiseizure medications: Report of the ILAE Task Force on Access to Treatment. Epilepsia, 2022, 63, 335-351.	2.6	12
59	The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study. Epilepsy and Behavior, 2020, 102, 106641.	0.9	10
60	Discontinuation of antiseizure medications in seizure-free patients with long-term follow-up: Patientsâ€™ profile, seizure recurrence, and risk factors. Epilepsy and Behavior, 2021, 117, 107871.	0.9	9
61	Italian Wikipedia and epilepsy: An infodemiological study of online information-seeking behavior. Epilepsy and Behavior, 2018, 81, 119-122.	0.9	8
62	History of violence/maltreatment and psychogenic non-epileptic seizures. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 8-12.	0.9	7
63	Treatment of epilepsy in light of the most recent advances. Lancet Neurology, The, 2019, 18, 7-8.	4.9	6
64	Rapid versus slow withdrawal of antiepileptic monotherapy in two-year seizure-free adults patients with epilepsy (RASLOW) study: A pragmatic multicentre, prospective, randomized, controlled study. Neurological Sciences, 2022, 43, 5133-5141.	0.9	6
65	Self-reporting versus clinical scrutiny: the value of adding questionnaires to the routine evaluation of seizure disorders. An exploratory study on the differential diagnosis between epilepsy and psychogenic nonepileptic seizures. Epilepsy and Behavior, 2019, 90, 191-196.	0.9	5
66	Self-Report questionnaires for the diagnosis of psychogenic non-epileptic seizures in clinical practice. A comprehensive review of the available instruments. Seizure: the Journal of the British Epilepsy Association, 2020, 79, 30-43.	0.9	4
67	The management of epilepsy in clinical practice: Do the timing and severity of the disease influence the priorities of patients and the caring physicians? Data from the EPINEEDS study. Epilepsy and Behavior, 2021, 114, 107201.	0.9	3
68	Immediate antiepileptic drug treatment, versus placebo, deferred, or no treatment for first unprovoked seizure. The Cochrane Library, 2021, 2021, CD007144.	1.5	3
69	Epidemiology and familial clustering of pediatric epilepsy in the geographic isolate of Ischia. Epilepsy Research, 2019, 154, 86-89.	0.8	2
70	Risk factors for neonatal seizures: A caseâ€"control study in the province of Parma, Italy. Epilepsy and Behavior, 2020, 107, 107075.	0.9	2
71	Peculiarities of Neurological Disorders and Study Designs. Frontiers of Neurology and Neuroscience, 2016, 39, 8-23.	3.0	1
72	Generation and validation of algorithms to identify subjects with dementia using administrative data. Neurological Sciences, 2019, 40, 2155-2161.	0.9	1

#	Article	IF	Citations
73	Coffee and Amyotrophic Lateral Sclerosis. , 2015, , 429-434.		0
74	In response: Towards a quantitative assessment of psychogenic nonepileptic seizures. Epilepsia, 2016, 57, 1011-1012.	2.6	0